Optimizing Beta Blocker Dosage in Women While Using the Wearable Cardioverter Defibrillator

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

Also called NCT04504188

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04504188
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04504188. Allocation not applicable; no masking; primary purpose treatment. Start 2021-03-08 (actual); primary completion 2024-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Optimizing Beta Blocker Dosage in Women While Using the Wearable Cardioverter Defibrillator
Acronym
OPT-BB WOMEN
Condition
Cardiomyopathies
Condition
Heart Failure
Intervention (Device)
Heart Rate Monitor Enhanced Treatment Optimization
Lead sponsor
Zoll Medical Corporation (class: industry)

Record details

Record id
cardio:ct-nct04504188
Content hash
56c56fb2ecd28842b1bf6c7554b4d4f7036a2895d0d9712af39d3edcc6285fcd